Market Hyperactivity: Bane of Biotech Deal-makers?

11:55 AM - 12:40 PM (EDT), Tuesday, June 15, 2021
Search General Info
Search Education
Search Partnering Companies

IPOs and after-market performance have continued at a breakneck pace. The influx of investor capital has seen a surge in formations of SPACs (special purpose acquisition companies) as an intriguing alternative for companies that want to go public because they can happen much faster than an initial public offering (IPO).  As equity markets soar, capital is plentiful to biotechs, so pharma has to either step up and pay up or miss out when it comes to M&A and collaborations.  Panelists will discuss how deal valuation trends are forcing creative and unique terms in negotiations to close strategic partnerships.

Sponsored By
Moderator
photo
Vice President, Business Development
Amgen Business Development
Speakers
photo
Vice President, Business Development
Amgen Business Development
photo
Managing Director, Life Sciences
Bain Capital, LP
photo
Executive Chairman & Chief Executive Officer
Jasper Therapeutics Inc.
photo
Managing Director, Global Head of Biotechnology Investment Banking
Goldman Sachs & Co.
photo
Managing Partner
Abingworth Management, Inc